

# Clinical trials of Capecitabine containing-regimen for advanced breast cancer (metastatic) in all type of patients

TrialResults-center [www.trialresultscenter.org](http://www.trialresultscenter.org)

## 1 capecitabine containing regimen

Trial	Treatments	Patients	Trials design and methods
<b>capecitabine vs CMF</b>			
Oshaughnessy , 2001 n=NA follow-up:	intermittent oral capecitabine 1,255 mg/m <sup>2</sup> twice daily (two weeks' treatment followed by a one-week rest period) versus intravenous CMF (cyclophosphamide, methotrexate, 5-fluorouracil [5-FU]) administered every three weeks	-line therapy for advanced/metastatic breast cancer	
<b>capecitabine vs control</b>			
Joensuu , 2009 [NCT00114816] n=753/747 follow-up:	three cycles of capecitabine and docetaxel followed by three cycles of cyclophosphamide, epirubicin, and capecitabine versus three cycles of docetaxel followed by three cycles of cyclophosphamide, epirubicin, and fluorouracil	women with axillary node-positive or high-risk node-negative breast cancer	open-label
<b>capecitabine vs cyclophosphamide, methotrexate, and 5-fluorouracil</b>			
Stockler , 2011 n=NA	-	-	
<b>capecitabine docetaxel vs docetaxel</b>			
GeparQuattro , 2010 [NCT00288002] n=NA follow-up:	-	Patients with large operable or locally advanced tumors, with hormone receptor-negative tumors, or with receptor-positive tumors but also clinically node-positive disease	
<b>capecitabine vs docetaxel + epirubicin</b>			
Mavroudis , 2010 n=NA follow-up:	docetaxel 75 mg/m(2) on day 1 plus capecitabine 950 mg/m(2) orally twice daily on days 1-14 (DC) in 21-day cycles versus docetaxel 75 mg/m(2) plus epirubicin 75 mg/m(2) (DE) on day 1	women with advanced breast cancer	
<b>capecitabine + docetaxel vs docetaxel alone</b>			

continued...

<b>Trial</b>	<b>Treatments</b>	<b>Patients</b>	<b>Trials design and methods</b>
Verma , 2005 n=255/256 follow-up:	21-day cycles of oral capecitabine 1250 mg/m <sup>2</sup> twice daily, on Days 1-14, plus docetaxel 75 mg/m <sup>2</sup> Day 1 versus docetaxel 100 mg/m <sup>2</sup> on Day 1	patients with anthracycline-pretreated metastatic breast carcinoma	
Miles , 2004 n=511 follow-up:	-	patients with anthracycline-pretreated advanced/metastatic breast cancer	
O'Shaughnessy , 2002 n=255/256 follow-up:	21-day cycles of oral capecitabine 1,250 mg/m <sup>2</sup> twice daily on days 1 to 14 plus docetaxel 75 mg/m <sup>2</sup> on day 1 versus docetaxel 100 mg/m <sup>2</sup> on day 1	patients with advanced breast cancer	
<b>capecitabine + docetaxel vs doxorubicin + cyclophosphamide</b>			
Lee , 2008 n=NA follow-up:	-	women with axillary node positive, stage II/III breast cancer	
<b>capecitabine MPA vs IV CT</b>			
Hori n=NA follow-up:	capecitabine, + medroxyprogesterone acetate (MPA) + cyclophosphamide versus 5-fluorouracil + adriamycin + CPA) plus MPA	metastatic breast cancer	
<b>capecitabine vs paclitaxel</b>			
Talbot , 2002 n=NA follow-up:	intermittent oral capecitabine (1255 mg m(-2) twice daily, days 1-14, (22 patients)) versus i.v. paclitaxel (175 mg m(-2),	patients with metastatic/advanced breast cancer pretreated with anthracyclines	
Moiseenko , 2000 n=NA follow-up:	-	-	
<b>capecitabine vs pegylated liposomal doxorubicin</b>			
Jger , 2010 n=NA	-	-	
<b>capecitabine vs vinorelbine</b>			
EORTC 10001 (Pajk) , 2008 n=NA follow-up:	capecitabine 1250 mg/m <sup>2</sup> orally bid days 1-14 versus vinorelbine 30 mg/m <sup>2</sup> i.v. days 1 and 8, both given every 3 weeks	patients with anthracycline- and taxane-pretreated metastatic breast cancer	

## References

### Oshaughnessy, 2001:

Oshaughnessy JA, Blum J, Moiseenko V, Jones SE, Miles D, Bell D, Rosso R, Mauriac L, Osterwalder B, Burger HU, Laws S, Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer. Ann

Oncol 2001;12:1247-54. [11697835]

**Joensuu, 2009:**

Joensuu H, Kellokumpu-Lehtinen PL, Huovinen R, Jukkola-Vuorinen A, Tanner M, Asola R, Kokko R, Ahlgren J, Auvinen P, Hemminki A, Pajja O, Helle L, Nuortio L, Villman K, Nilsson G, Lahtela SL, Lehti K, Pajunen M, Poikonen P, Nyandoto P, Kataja V, Bono P, Adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for breast cancer: an open-label, randomised controlled trial. *Lancet Oncol* 2009;10:1145-51. [19906561] [10.1016/S1470-2045\(09\)70307-9](https://doi.org/10.1016/S1470-2045(09)70307-9)

Joensuu H, Kellokumpu-Lehtinen PL, Huovinen R, Jukkola-Vuorinen A, Tanner M, Kokko R, Ahlgren J, Auvinen P, Lahdenper O, Kosonen S, Villman K, Nyando Adjuvant Capecitabine in Combination With Docetaxel, Epirubicin, and Cyclophosphamide for Early Breast Cancer: The Randomized Clinical FinXX Trial. *JAMA Oncol* 2017;: [28253390]

**Stockler, 2011:**

Stockler MR, Harvey VJ, Francis PA, Byrne MJ, Ackland SP, Fitzharris B, Van Hazel G, Wilcken NR, Grimison PS, Nowak AK, Gainford MC, Fong A, Paksec L, Sourjina T, Zannino D, GebSKI V, Simes RJ, Forbes JF, Coates AS Capecitabine versus classical cyclophosphamide, methotrexate, and fluorouracil as first-line chemotherapy for advanced breast cancer. *J Clin Oncol* 2011;29:4498-504 [22025143] [10.1200/JCO.2010.33.9101](https://doi.org/10.1200/JCO.2010.33.9101)

**GeparQuattro, 2010:**

von Minckwitz G, Rezaei M, Loibl S, Fasching PA, Huober J, Tesch H, Bauerfeind I, Hilfrich J, Eidtmann H, Gerber B, Hanusch C, Khn T, du Bois A, Blohmer JU, Thomssen C, Dan Costa S, Jackisch C, Kaufmann M, Mehta K, Untch M, Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study. *J Clin Oncol* 2010;28:2015-23. [20308671] [10.1200/JCO.2009.23.8303](https://doi.org/10.1200/JCO.2009.23.8303)

**Mavroudis, 2010:**

Mavroudis D, Papakotoulas P, Ardavanis A, Syrigos K, Kakolyris S, Ziras N, Kouroussis C, Malamos N, Polyzos A, Christophyllakis C, Kentepozidis N, Georgoulas V, , Randomized phase III trial comparing docetaxel plus epirubicin versus docetaxel plus capecitabine as first-line treatment in women with advanced breast cancer. *Ann Oncol* 2010;21:48-54. [19906761] [10.1093/annonc/mdp498](https://doi.org/10.1093/annonc/mdp498)

**Verma, 2005:**

Verma S, Maraninchi D, O'Shaughnessy J, Jamieson C, Jones S, Martn M, McKendrick J, Miles D, Twelves C, Hornberger J, Capecitabine plus docetaxel combination therapy. *Cancer* 2005;103:2455-65. [15892043] [10.1002/cncr.21122](https://doi.org/10.1002/cncr.21122)

**Miles, 2004:**

Miles D, Vukelja S, Moiseyenko V, Cervantes G, Mauriac L, Van Hazel G, Liu WY, Ayoub JP, O'Shaughnessy JA, Survival benefit with capecitabine/docetaxel versus docetaxel alone: analysis of therapy in a randomized phase III trial. *Clin Breast Cancer* 2004;5:273-8. [15507172]

**O'Shaughnessy, 2002:**

O'Shaughnessy J, Miles D, Vukelja S, Moiseyenko V, Ayoub JP, Cervantes G, Fumoleau P, Jones S, Lui WY, Mauriac L, Twelves C, Van Hazel G, Verma S, Leonard R, Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. *J Clin Oncol* 2002;20:2812-23. [12065558]

**Lee, 2008:**

Lee KS, Ro J, Nam BH, Lee ES, Kwon Y, Kwon HS, Chung KW, Kang HS, Kim EA, Kim SW, Shin KH, Kim SK, A randomized phase-III trial of docetaxel/capecitabine versus doxorubicin/cyclophosphamide as primary chemotherapy for patients with stage II/III breast cancer. *Breast Cancer Res Treat* 2008;109:481-9. [17653851] [10.1007/s10549-007-9672-y](https://doi.org/10.1007/s10549-007-9672-y)

**Hori, 0:**

Hori T, Kodama H, Nishimura S, Hatano T, Okamura R, Fujii K, Kudo T, Inamoto T, Sawai K, Kobayashi M, Ogawa H, Yoshimura N, Hiraoka M, A randomized study comparing oral and standard regimens for metastatic breast cancer. *Oncol Rep* ;8:1067-71. [11496318]

**Talbot, 2002:**

Talbot DC, Moiseyenko V, Van Belle S, O'Reilly SM, Alba Conejo E, Ackland S, Eisenberg P, Melnychuk D, Pienkowski T, Burger HU, Laws S, Osterwalder B, Randomised, phase II trial comparing oral capecitabine (Xeloda) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines. *Br J Cancer* 2002;86:1367-72. [11986765] [10.1038/sj.bjc.6600261](https://doi.org/10.1038/sj.bjc.6600261)

**Moiseenko, 2000:**

Moiseenko VM, O'Reilly SM, Dalbot DC, Van Belle S, Gordon RJ, Griffin T, Osterwalder B, [A comparative randomized phase-II study of Xeloda (capecitabine) and paclitaxel in patients with breast cancer progressing after anthracycline antibiotics] *Vopr Onkol* 2000;46:285-9. [[10976273](#)]

**Jger, 2010:**

Jger E, Al-Batran S, Saupe S et al. A randomized phase III study evaluating pegylated liposomal doxorubicin (PLD) versus capecitabine (CAP) as first-line therapy for metastatic breast cancer (MBC): Results of the PELICAN study *J Clin Oncol* 2010;28(15 suppl):1022.

**EORTC 10001 (Pajk), 2008:**

Pajk B, Cufer T, Canney P, Ellis P, Cameron D, Blot E, Vermorken J, Coleman R, Marreaud S, Bogaerts J, Basaran G, Piccart M, Anti-tumor activity of capecitabine and vinorelbine in patients with anthracycline- and taxane-pretreated metastatic breast cancer: findings from the EORTC 10001 randomized phase II trial. *Breast* 2008;17:180-5. [[17976988](#)]  
[10.1016/j.breast.2007.09.002](#)

## 2 About TrialResults-center.org

TrialResults-center is an innovative knowledge database that collects the results of RCTs and provides dynamic interactive systematic reviews and meta-analysis in the field of all major heart and vessels diseases.

The TrialResults-center database provides a unique view of the treatment efficacy based on all data provided directly from clinical trial results, offering a valuable alternative to personal bibliographic search, published meta-analysis, etc. Furthermore, it would allow comparing easily the various concurrent therapeutic for the same clinical condition.

Rigorous meta-analysis method is used to populate TrialResults-center: widespread search of published and non published trials, study selection using pre-specified criteria, data extraction using standard form.

TrialResults-center is continually updated on a weekly basis. We continually search all new results (whatever their publication channel) and these news results are immediately added to the database with a maximum of 1 week.

TrialResults-center is non-profit and self-funded.